Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Checking PSA levels too soon after prostate cancer surgery can lead to overtreatment, study suggests
2.
Q&A: When will individuals be able to receive customized cancer vaccines?
3.
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?
4.
AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC
5.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
1.
Colorectal Cancer Uncovered: CME, Case Studies, and Clinical Strategies
2.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
3.
Unlocking the Mysteries of ICD 10 Code Normocytic Anemia
4.
Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide
5.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part III
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
5.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge